Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder

S. Trivedi, Pranab Patnaik, Y. Ramole, F. Khan, R. Srivastava, U. S. Dwivedi
{"title":"Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder","authors":"S. Trivedi, Pranab Patnaik, Y. Ramole, F. Khan, R. Srivastava, U. S. Dwivedi","doi":"10.1177/1179561119864907","DOIUrl":null,"url":null,"abstract":"Background: This study compared urinary and serum nerve growth factor levels and serum C-reactive protein levels in patients with overactive bladder, before and after treatment with antimuscarinic agents, to evaluate their diagnostic and therapeutic importance. Methods: This was a prospective case-control study conducted between February 2014 and December 2014 which included patients with a confirmed diagnosis of overactive bladder (overactive bladder group) and healthy controls (control group). All patients visiting urology out-patient department with urgency, frequency, and urge incontinence were assessed for overactive bladder and, if eligible, were enrolled in the study. Biomarkers were evaluated before in both groups and after antimuscarinic treatment in the overactive bladder group. Results: Overall, 80 participates were enrolled (overactive bladder, n = 40; control, n = 40). The mean age was not different between the two groups (overactive bladder, 48.6 years; control, 46.9 years [P = 1.01]) and females were more in both the groups (60% and 55%, respectively). The majority (70%) of patients presented with frequency and urgency. After 3 months of treatment with antimuscarinics, the mean overactive bladder symptom score decreased significantly from 8.4 to 4.85 (P < .001). The mean urinary and serum nerve growth factor levels and serum C-reactive protein levels also decreased significantly from baseline after 3 months of treatment with antimuscarinics (24.78 pg/mL, 22.46 pg/mL, 0.89 mg/L, respectively; P < .0001). Conclusions: Measurement of urinary and serum nerve growth factor levels has diagnostic and therapeutic potential in patients with overactive bladder.","PeriodicalId":89908,"journal":{"name":"Clinical medicine insights. Urology","volume":"63 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical medicine insights. Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1179561119864907","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: This study compared urinary and serum nerve growth factor levels and serum C-reactive protein levels in patients with overactive bladder, before and after treatment with antimuscarinic agents, to evaluate their diagnostic and therapeutic importance. Methods: This was a prospective case-control study conducted between February 2014 and December 2014 which included patients with a confirmed diagnosis of overactive bladder (overactive bladder group) and healthy controls (control group). All patients visiting urology out-patient department with urgency, frequency, and urge incontinence were assessed for overactive bladder and, if eligible, were enrolled in the study. Biomarkers were evaluated before in both groups and after antimuscarinic treatment in the overactive bladder group. Results: Overall, 80 participates were enrolled (overactive bladder, n = 40; control, n = 40). The mean age was not different between the two groups (overactive bladder, 48.6 years; control, 46.9 years [P = 1.01]) and females were more in both the groups (60% and 55%, respectively). The majority (70%) of patients presented with frequency and urgency. After 3 months of treatment with antimuscarinics, the mean overactive bladder symptom score decreased significantly from 8.4 to 4.85 (P < .001). The mean urinary and serum nerve growth factor levels and serum C-reactive protein levels also decreased significantly from baseline after 3 months of treatment with antimuscarinics (24.78 pg/mL, 22.46 pg/mL, 0.89 mg/L, respectively; P < .0001). Conclusions: Measurement of urinary and serum nerve growth factor levels has diagnostic and therapeutic potential in patients with overactive bladder.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血清和尿液生物标志物在评估和治疗膀胱过度活动患者中的作用
背景:本研究比较了抗毒蕈碱药物治疗前后膀胱过动症患者尿、血清神经生长因子水平和血清c反应蛋白水平,以评价其诊断和治疗意义。方法:2014年2月至2014年12月进行前瞻性病例对照研究,纳入确诊为膀胱过动症的患者(膀胱过动症组)和健康对照组(对照组)。所有急迫性、频繁性和急迫性尿失禁的泌尿科门诊患者都被评估为膀胱过度活动,如果符合条件,则被纳入研究。两组患者在抗毒蕈碱治疗前及膀胱过度活动组患者在抗毒蕈碱治疗后进行生物标志物评估。结果:共纳入80名参与者(膀胱过度活动,n = 40;对照组,n = 40)。两组患者的平均年龄无显著差异(膀胱过度活动,48.6岁;对照组为46.9岁[P = 1.01]),两组女性患病率均高于对照组(分别为60%和55%)。大多数(70%)患者出现频率和急迫性。治疗3个月后,膀胱过度活动症状平均评分由8.4降至4.85,差异有统计学意义(P < 0.001)。抗毒蕈素治疗3个月后,尿和血清神经生长因子水平和血清c反应蛋白水平也较基线显著下降(分别为24.78 pg/mL, 22.46 pg/mL, 0.89 mg/L);p < 0.0001)。结论:测定尿液和血清神经生长因子水平对膀胱过动症患者具有诊断和治疗价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Prevalence and Forecast Prevalence of Overactive Bladder in the Medicare Population Clinical Outcomes of Retrograde Intrarenal Surgery as a Primary Treatment for Staghorn Calculi: A Single-Center Experience Urinary pH as a Target in the Management of Lithiasic Patients in Real-World Practice: Monitoring and Nutraceutical Intervention for a Nonlithogenic pH Range Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1